Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Rivoli, Giulia
SELECT MDS-1, NCT04797780 / 2020-004528-40: Tamibarotene Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome	Recruiting	3	550	Europe, Canada, US, RoW	Tamibarotene, SY-1425, Placebo, Azacitidine	Syros Pharmaceuticals	Myelodysplastic Syndromes	11/24	02/29
GIMEMA, NCT06657846: HRQoL and Financial Toxicity in Patients with VEXAS Syndrome	Not yet recruiting	N/A	100	Europe		Gruppo Italiano Malattie EMatologiche dell'Adulto	VEXAS	02/25	06/25
Lombardi, Serena
No trials found